Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592383 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01592383 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 2 participants.
The verdict
NCT01592383, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer. Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other cancers, but erlotinib has not been approved for malignant peritoneal mesothelioma. This research is being done because there is no current standard treatment for malignant peritoneal mesothelioma and the study doctors want to see how erlotinib affects malignant peritoneal mesothelioma.
Interventions
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592383
The ClinicalTrials.gov registry entry for NCT01592383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erlotinib hydrochloride is the first listed.
NCT01592383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592383 about?
NCT01592383 is a clinical study titled "Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma". The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer. Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other cancers, but erlotini...
What is the current status of trial NCT01592383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-06. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01592383?
The interventions under investigation include: erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01592383?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.